97 related articles for article (PubMed ID: 11231452)
1. Direct detection of cellular immune responses to cancer vaccines.
Mosca PJ; Hobeika AC; Clay TM; Morse MA; Lyerly HK
Surgery; 2001 Mar; 129(3):248-54. PubMed ID: 11231452
[TBL] [Abstract][Full Text] [Related]
2. Immune monitoring of T-cell responses in cancer vaccine development.
Keilholz U; Martus P; Scheibenbogen C
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2346s-2352s. PubMed ID: 16609057
[TBL] [Abstract][Full Text] [Related]
3. Proteomics for monitoring immune responses to cancer vaccines.
Mosca PJ; Lyerly HK; Ching CD; Hobeika AC; Clay TM; Morse MA
Curr Opin Mol Ther; 2003 Feb; 5(1):39-43. PubMed ID: 12669469
[TBL] [Abstract][Full Text] [Related]
4. Quantitating therapeutically relevant T-cell responses to cancer vaccines.
Hobeika AC; Clay TM; Mosca PJ; Lyerly HK; Morse MA
Crit Rev Immunol; 2001; 21(1-3):287-97. PubMed ID: 11642610
[TBL] [Abstract][Full Text] [Related]
5. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
6. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccines for cancer.
Boyd D; Hung CF; Wu TC
IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
[TBL] [Abstract][Full Text] [Related]
8. Current developments in cancer vaccines and cellular immunotherapy.
Ribas A; Butterfield LH; Glaspy JA; Economou JS
J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
[TBL] [Abstract][Full Text] [Related]
9. Local delivery of poxvirus vaccines for melanoma.
Hörig H; Kaufman HL
Semin Cancer Biol; 2003 Dec; 13(6):417-22. PubMed ID: 15001160
[TBL] [Abstract][Full Text] [Related]
10. Monitoring cellular immune responses to cancer immunotherapy.
Morse MA; Clay TM; Hobeika AC; Mosca PJ; Lyerly HK
Curr Opin Mol Ther; 2001 Feb; 3(1):45-52. PubMed ID: 11249731
[TBL] [Abstract][Full Text] [Related]
11. [MHC tetramers: tracking specific immunity].
Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
[TBL] [Abstract][Full Text] [Related]
12. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
13. Potency assays for therapeutic live whole cell cancer vaccines.
Petricciani J; Egan W; Vicari G; Furesz J; Schild G
Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
[TBL] [Abstract][Full Text] [Related]
14. Telomerase as a universal tumor antigen for cancer vaccines.
Beatty GL; Vonderheide RH
Expert Rev Vaccines; 2008 Sep; 7(7):881-7. PubMed ID: 18767939
[TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?
Reilly RT; Emens LA; Jaffee EM
Curr Opin Investig Drugs; 2001 Jan; 2(1):133-5. PubMed ID: 11527005
[TBL] [Abstract][Full Text] [Related]
16. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens.
Mattner F; Fleitmann JK; Lingnau K; Schmidt W; Egyed A; Fritz J; Zauner W; Wittmann B; Gorny I; Berger M; Kirlappos H; Otava A; Birnstiel ML; Buschle M
Cancer Res; 2002 Mar; 62(5):1477-80. PubMed ID: 11888923
[TBL] [Abstract][Full Text] [Related]
18. New understanding of immunological mechanisms.
Saalmüller A
Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
[TBL] [Abstract][Full Text] [Related]
19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
20. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
